表紙
市場調查報告書

免疫查核點抑制劑市場: 市場機會分析及未來預測

Immune Checkpoint Inhibitors Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

出版商 Coherent Market Insights 商品編碼 817599
出版日期 內容資訊 英文 238 Pages
商品交期: 2-3個工作天內
價格
Back to Top
免疫查核點抑制劑市場: 市場機會分析及未來預測 Immune Checkpoint Inhibitors Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
出版日期: 2019年03月25日內容資訊: 英文 238 Pages
簡介

本報告提供免疫查核點抑制劑的世界市場調查,市場概要,各類型,用途,地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 前提條件
  • 簡稱

第2章 市場概要

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場片段:各類藥物
    • 市場片段:各用途
    • 市場片段:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 流行病學
  • 聯盟和合作關係
  • 主要的FDA的認證與產品銷售方案
  • 開發平台分析
  • 法規方案
  • 退還方案
  • PEST分析
  • 波特的五力分析

第4章 免疫查核點抑制劑市場:各類藥物

  • 簡介
  • PD-1 抑制劑
  • PD-L1 抑制劑
  • CTL-4 抑制劑
  • IDO 抑制劑
  • 淋巴球活性化遺傳基因3 抑制劑

第5章 免疫查核點抑制劑市場:各用途

  • 簡介
  • 肺癌症
  • 頭頸椎癌症
  • 皮膚癌症(黑色素瘤、默克細胞癌)
  • 血液癌症(淋巴瘤)
  • 膀胱癌(尿路表皮癌症)
  • 腎臟/腎臟癌症
  • 大腸癌症
  • 乳癌
  • 其他

第6章 免疫查核點抑制劑市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 免疫查核點抑制劑市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 中南美
  • 中東
  • 非洲

第8章 競爭環境

  • 熱圖分析
  • 企業簡介
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.

第9章 Section

  • 參考文獻
  • 調查方法
  • 關於Coherent Market Insights
目錄

Immune checkpoint inhibitor products come under biologic therapeutic products. Biologic manufacturers require similar kind of approvals such as drugs from the U.S. Food & Drug Administration prior to bringing the product into market. However, unlike drugs, biologics require Biologics License Applications (BLA) to be filed with the Center for Biologics Evaluation and Research (CBER). Initiatives undertaken by the governments include funding is expected to drive growth of the immune checkpoint inhibitors market. For instance, in 2017, National Institutes of Health partnered with 11 leading biopharmaceutical companies such as AbbVie and Amgen, Inc. to accelerate development of new immunotherapies.

Market Dynamics

Global Immune checkpoint inhibitors market is driven by factors such as increasing prevalence of cancer, active research and development by leading manufacturers through collaborations and individual research, and robust pipeline of immune checkpoint inhibitor combination therapies. According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people suffering from cancer worldwide. There are many immune checkpoint inhibitors combination therapies in the pipeline. Immune checkpoint inhibitors has proven clinical profile and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost global immune checkpoint inhibitors market growth over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of Global Immune Checkpoint Inhibitors Market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2018-2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the Global Immune Checkpoint Inhibitors Market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, By Technology up-gradation, market expansion, and marketing tactics
  • The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Global Immune Checkpoint Inhibitors Market

Detailed Segmentation:

  • Global Immune Checkpoint Inhibitors Market, By Drug Class:
    • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
    • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
    • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
    • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    • Lymphocyte-Activation Gene 3 Inhibitors
  • Global Immune Checkpoint Inhibitors Market, By Cancer Type:
    • Lung Cancer
    • Head & Neck Cancer
    • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    • Blood Cancer (Lymphoma)
    • Bladder Cancer (Urothelial Carcinoma)
    • Renal/Kidney Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Others
  • Global Immune Checkpoint Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Immune Checkpoint Inhibitors Market, By Geography:
    • North America
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Europe
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Russia
      • Spain
      • Rest of Europe
    • Asia Pacific
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of APAC
    • Latin America
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of LATAM
    • Middle East
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • North Africa
      • Central Africa
      • South Africa
  • Company Profiles
    • Bristol-Myers Squibb Company*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Application
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Epidemiology
  • Collaborations & Partnerships
  • Major FDA Approvals & Product Launch Scenario
  • Pipeline Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • PEST Analysis
  • Porter's Five Forces Analysis

4. Global Immune Checkpoint Inhibitors Market, By Drug Class, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Programmed Death Receptor-1 (PD-1) Inhibitors
    • Pembrolizumab (Keytruda)
    • Nivolumab (Opdivo)
    • Cemiplimab (Libtayo)
    • Others
  • Programmed Death-Ligand 1 (PD-L1) Inhibitors
    • Atezolizumab (Tecentriq)
    • Avelumab (Bavencio)
    • Durvalumab (Imfinzi)
  • CTL-4 Checkpoint Inhibitor
    • Ipilimumab (Yervoy)
  • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
  • Lymphocyte-Activation Gene 3 Inhibitors

5. Global Immune Checkpoint Inhibitors Market, By Application, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Head & Neck Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Blood Cancer (Lymphoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Bladder Cancer (Urothelial Carcinoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Renal/Kidney Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)

6. Global Immune Checkpoint Inhibitors Market, By Distribution Channel, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)

7. Global Immune Checkpoint Inhibitors Market, By Regions, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2026
  • North America
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • F. Hoffmann-La Roche AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • ImmunOs Therapeutics AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Immutep Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • NewLink Genetics Corporation
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Ono Pharmaceutical Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top